Chiron IL-2 HIV trial halted
Executive Summary
Chiron halts Phase III study for IL-2 (aldesluekin) in patients with HIV. "Since the primary endpoint for the SILCAAT trial is time to first AIDS-defining event or death, decreases in clinical events and disease progression make the duration of time required to maintain a study of this magnitude infeasible for Chiron," President Craig Wheeler said. Chiron markets aldesluekin as Proleukin for metastatic renal cell carcinoma and metastatic melanoma...